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Abstract
Background: Increasingly, treatment for opioid use disorder (OUD) is offered in integrated treatment models
addressing both substance use and other health conditions within the same system. This often includes offering
medications for OUD in general medical settings. It remains uncertain whether integrated OUD treatment models are
preferred to non-integrated models, where treatment is provided within a distinct treatment system. This study aimed
to explore preferences for integrated versus non-integrated treatment models among people with OUD and examine
what factors may influence preferences.
Methods: This qualitative study recruited participants (n = 40) through Craigslist advertisements and flyers posted
in treatment programs across the United States. Participants were 18 years of age or older and scored a two or higher
on the heroin or opioid pain reliever sections of the Tobacco, Alcohol, Prescription Medications, and Other Substances
(TAPS) Tool. Each participant completed a demographic survey and a telephone interview. The interviews were coded
and content analyzed.
Results: While some participants preferred receiving OUD treatment from an integrated model in a general medical
setting, the majority preferred non-integrated models. Some participants preferred integrated models in theory but
expressed concerns about stigma and a lack of psychosocial services. Tradeoffs between integrated and non-inte‑
grated models were centered around patient values (desire for anonymity and personalization, fear of consequences),
the characteristics of the provider and setting (convenience, perceived treatment effectiveness, access to services),
and the patient-provider relationship (disclosure, trust, comfort, stigma).
Conclusions: Among this sample of primarily White adults, preferences for non-integrated versus integrated OUD
treatment were mixed. Perceived benefits of integrated models included convenience, potential for treatment per‑
sonalization, and opportunity to extend established relationships with medical providers. Recommendations to make
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integrated treatment more patient-centered include facilitating access to psychosocial services, educating patients
on privacy, individualizing treatment, and prioritizing the patient-provider relationship. This sample included very few
minorities and thus findings may not be fully generalizable to the larger population of persons with OUD. Nonethe‑
less, results suggest a need for expansion of both OUD treatment in specialty and general medical settings to ensure
access to preferred treatment for all.
Keywords: Patient preference, Opioid use disorder, Treatment model, Integrated treatment

Background
Trends in opioid use disorder (OUD) treatment

With rising rates of opioid overdose deaths in the United
States (US; [1]), more Americans are seeking treatment
for opioid use disorder (OUD; [2, 3]). Despite an increase
in admissions for OUD treatment in the US [3], there has
been little expansion of specialty substance use treatment
[4, 5]. Consequently, less than ten percent of American
adults with an OUD received past-year treatment within
a specialty substance use treatment program [6]. Though
medications for opioid use disorder (MOUD), including
methadone, buprenorphine, and naltrexone, are widely
recognized as effective treatments for OUD [7–9], few
patients receive these [10]. In 2017, only 38% of substance
use treatment facilities nationwide offered MOUD [11].
As a result, more individuals are seeking treatment for
substance use in non-specialty settings, including general
medical settings [12, 13]. Providing treatment in nonspecialty settings is critical to increase access to effective
treatment, like MOUD, and reflects an important shift in
the models of care for OUD and other substance use disorders in the US.

Integrated versus non‑integrated treatment
models
Historically, care for behavioral and physical health conditions was offered in separate treatment systems [14–
17]. However, recent legislation supported the expansion
and integration of OUD and behavioral health treatment
into general medical settings [14, 18–21]. Integrated
treatment models systematically address both behavioral
and physical health conditions within the same treatment
system or program [22]. A range of integrated models for
treating OUD have been implemented, often co-locating
OUD treatment into primary care settings [23–26]. These
models vary based on their level of primary care and
behavioral health collaboration and the services offered
[23, 25, 27, 28]. While some integrated programs offer
MOUD only and refer patients for additional psychosocial services, others also provide psychosocial treatment
services [24, 26, 29]. Evidence suggests that integrated
treatment models within primary care are cost-effective,
reduce treatment attrition, and may improve both healthrelated quality of life and satisfaction with treatment

for patients with OUD [25, 28, 30–33]. Other settings,
including pharmacies [34, 35], obstetrics and gynecology practices [36–38], and emergency departments [39]
have also started to integrate MOUD and other OUD
treatments.

Patient preference for OUD treatment models
Although emerging evidence suggests that integrated
treatment models are effective and associated with higher
retention rates than non-integrated models of OUD
treatment [28, 40], less is known about whether patients
prefer integrated or non-integrated models. According to
the Bastemeijer et al. taxonomy of patient values, patient
preference is influenced by three primary considerations:
1) the patient’s values, including their desire for uniqueness and autonomy; 2) the characteristics of the provider
valued by the patient, including their professionalism,
responsiveness, and compassion; and 3) the patientprovider relationship, including their partnership and
empowerment [41]. Consideration of patient preference
is critical in the context of treating conditions that may
necessitate long-term treatment, like OUD [42–44].
Few studies have examined patient preference for
substance use disorder (SUD) treatment models [25]. A
sample of patients at five clinics offering integrated primary care and behavioral healthcare indicated a moderate preference for integrated care on one survey item
[45]. In another survey study, individuals on a web-based
research panel were presented with vignettes describing either integrated or non-integrated treatment for
behavioral health conditions. Among a subgroup of participants who screened positive for a SUD, 25% were willing to enter treatment when presented with the vignette
describing usual, non-integrated care, while 37% were
willing to enter integrated treatment [46]. These findings
suggested substantial individual differences in preferences for treatment model that should be explored.
Several studies have assessed patient preference for
integrated substance use and human immunodeficiency
virus (HIV) treatment [47–50]. Overall, surveyed individuals generally expressed positive views regarding
integrated versus non-integrated HIV and substance use
treatment [47–50]. Patients appreciated the convenience
of having a single team of providers [47, 48, 50] and felt
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their integrated care was comprehensive and highly personalized [48, 50]. Despite this, some patients preferred
receiving substance use treatment from providers in specialty clinics not associated with their HIV care [48, 50]
because of concerns that HIV providers may lack training and knowledge about treating substance use [48] and
because of the additional structure offered in specialty
substance use treatment programs [48, 50].
Few studies have assessed preferences for integrated
OUD treatment located in settings other than HIV clinics, such as primary care, emergency departments, or
pharmacies. In a cross-sectional study of people who
used opioids at a syringe services program, 62% (n = 49)
were willing to initiate buprenorphine treatment in a
specialty substance use treatment program while 59%
(n = 47) were willing to initiate in a primary care clinic
[51]. Two qualitative studies found that patients receiving buprenorphine in primary care settings generally
reported being satisfied with their care [52, 53]. These
patients appreciated the convenience of being treated for
both physical health and substance use concerns in one
setting and felt that the primary care providers and staff
were courteous and respectful [52]. While these studies examined satisfaction and willingness to initiate care
among patients with OUD, it remains uncertain whether
people with OUD prefer integrated versus non-integrated treatment models and what factors may influence
preferences and perceptions for these treatment models.

Aims and objectives
The goals of the present study were to examine preferences for integrated versus non-integrated treatment
models among adults with OUD and to explore the factors influencing these preferences. Qualitative interviews
were conducted to provide an in-depth understanding of
factors shaping preferences for treatment models, as well
as participant preference for different MOUD formulations [54]. This article focuses on the results from the
analysis exploring preferences for OUD treatment models, which the authors planned to use to refine a survey
instrument to examine preferences for OUD treatment in
a subsequent study.
Methods
Design

Qualitative interviews were conducted by telephone with
adults reporting non-medical use of opioid pain relievers,
heroin, and/or fentanyl. The semi-structured interview
guide (Additional file 1) was developed with input from
experts in qualitative methodology and OUD treatment,
after completing a literature review of studies examining OUD treatment preferences. This interview guide
was not pilot tested but was iteratively revised after
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conducting the first two interviews based on participants’
understanding of the prompts. Interviews focused on
participants’ opioid use, experiences with treatment for
OUD, and preferences for MOUD formulation and integrated treatment models. Though findings were organized by the domains from the Bastemeijer et al. taxonomy
of patient values [41], participants were first asked more
open-ended and exploratory questions about their
thoughts and preferences surrounding treatment models.
If participants were not forthcoming with their thoughts,
the interviewer followed up with questions regarding
the participants’ prior experiences with general medical
providers and level of comfort discussing substance use
with general medical providers. Each participant also
completed a brief survey created for this study, which
collected data on participant demographics, opioid use,
and history of receiving OUD treatment. No repeat interviews were conducted. The Dartmouth College Committee for the Protection of Human Subjects approved all
study materials and methods.

Participants and setting
Forty participants completed interviews in February and
March of 2018. Thirty were recruited through Craiglist,
and ten were recruited through flyers posted in substance
use treatment programs. Individuals under 18 years of
age were excluded. Other inclusion criteria included
English-language proficiency, current US residence, and
a score of two or higher on the heroin and/or opioid pain
reliever sections of the Tobacco, Alcohol, Prescription
Medications, and Other Substances (TAPS) Tool [55, 56],
suggesting a past-year OUD diagnosis. Once determined
eligible, no participants refused to participate or dropped
out.
Participants were purposively recruited to ensure
diversity in geographic location and MOUD experience. Because MOUD experience may influence OUD
treatment model preference, the researchers purposively recruited individuals with and without MOUD
experience through advertisements posted in the “Help
Wanted-Gig” section of Craigslist, an online classifieds website. These advertisements were posted in nine
regions of the US, including urban and rural regions in
the Northeast, Southeast, Midwest, Northwest, and
Southwest known to have high rates of opioid overdose
[57]. Flyers were also posted in six specialty substance
use treatment programs affiliated with the National Drug
Abuse Treatment Clinical Trials Network in the states
of New York, Texas, Washington, Oregon, and Ohio to
recruit individuals receiving MOUD treatment. These
programs were all specialty substance use treatment
programs. The flyers and advertisements were posted
in English. We planned to recruit up to 40 participants
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and continue interviews until thematic saturation was
reached with the added proviso that saturation was not
understood as an event but an incremental assessment of
the substantiation of themes [58].

Procedures
Participants contacted the research team by phone or
email to schedule an interview. All interviews were conducted by the first author (ECS), a female health policy
and clinical practice doctoral candidate. This interviewer
had received doctoral-level training on qualitative interviewing and also had experience conducting interviews
about opioid and other substance use in several previous studies [59–61]. The interviewer had no relationships
with any participants prior to their involvement in the
study. When participants were introduced to the study,
the researcher introduced herself as part of a research
team studying treatment for OUD. She explained this
study was part of her doctoral research and informed
participants that the primary purpose was to learn about
participants’ experiences and preferences for different
treatment for OUD. The interviewer explained that there
were no right answers to any of the study questions and
told participants that the research team hoped to learn
from their experiences and opinions.
After describing the study, the interviewer read aloud
the study information sheet and answered questions
about the study. Once participants provided oral consent,
they were screened to determine eligibility. Because the
study recruited individuals from across the US, all interviews were conducted by telephone. Usually participants
were alone while completing the interviews, though in
several interviews the interviewer became aware of the
presence of other household members. Participants
completed the brief demographic survey, followed by
the semi-structured interview. To facilitate the interview, participants who were willing to share their email
address were sent a Treatment Model Comparison Chart
(Additional file 2) created for the study, which described
integrated versus non-integrated treatment models. If
participants did not wish to share an email address, the
interviewer read aloud the information contained in this
chart.
Interviews were audio recorded. Recordings were
uploaded to a secure electronic folder hosted by Dartmouth College and were only identified with the study
identification number. The interviewer also wrote brief
field notes on a spreadsheet after each interview to facilitate recall of contextual variables during analysis and
interpretation. Though phone numbers and a pseudonym were also collected for each participant to facilitate
scheduling, these were deleted once all interviews were
complete. As compensation for their time, participants
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were sent a $40 gift card by email, postal mail, or text
message.

Analysis
All interviews were transcribed verbatim. Half of the
interviews were transcribed by a third-party transcription
service, and the other half were transcribed by members
of the research team using Express Scribe transcription
software [62]. Each transcript was reviewed by at least
one member of the research team. Transcriptions were
not returned to participants for comment or corrections.
After transcription, any potentially identifying information, such as person or street names, was removed from
every transcript. Transcripts were then analyzed using a
directed content analytic approach [63–65]. A preliminary code list was developed deductively based on the
topics and domains covered in the study interview guide.
Initial coding categories were determined based on the
interview guide, which was created using the existing
literature about patient preference for OUD treatment.
Once the preliminary code list was developed by one analyst (ECS), transcripts were uploaded to Atlas.ti [66] for
analysis. First-cycle coding was completed by two analysts (ECS, SKM), who initially coded two transcripts collaboratively. After reviewing each transcript, all text was
coded using the predetermined codes. Text that did not
fit into the pre-determined codelist was marked. The analysts discussed these marked sections and emerging coding categories weekly. New codes were then inductively
generated, and the code list was revised. The analysts
then collectively analyzed two additional transcripts,
until reaching consensus that no new categories were
conceptualized. At this point, the analysts independently
coded the remaining 36 transcripts, meeting weekly to
discuss coding and resolving through discussion.
The subtheme analysis was conducted by four analysts (ECS, SKM, OW, SAM). Coded text segments were
exported to Microsoft Word. For every code, two analysts
reviewed the coded passages line by line. Text segments
were grouped based on emerging themes and subthemes.
The analysis team met regularly to discuss and compare
findings. Text segments stating preference for integrated
versus non-integrated treatment were counted quantitatively by two analysts working independently who met
and compared findings weekly (ECS, OW). Throughout
the analysis, discrepancies were resolved through discussion. The Bastemeijer et al. taxonomy [41] was used as a
heuristic device to conceptualize the findings from this
analysis by examining advantages and disadvantages of
integrated versus non-integrated treatment models. This
taxonomy includes three primary considerations that
influence patient preference: patient values, characteristics of the provider, and the patient-provider relationship
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[41]. In addition to provider characteristics, characteristics of the treatment setting emerged as an additional
important theme for participants. The Bastemeijer et al.
taxonomy was thus modified to include this theme after
completion of the subtheme analysis. Participants did not
provide feedback on the findings.

Results
Participant characteristics

Participants’ average age was 36.5 (standard deviation
[SD] = 10.9) years. Forty percent of participants (n = 16)
were female, while 60.0% (n = 24) were male. The majority of participants were White (n = 36; 90.0%), with only
four Black or African American participants (n = 4;
10.0%). Eighty percent of participants were not Hispanic or Latino (n = 32). Based on the National Center
for Health Statistics Classification [67], 18 participants
(45.0%) resided in large metropolitan regions, 13 (32.5%)
in medium metropolitan regions, and 8 (20.0%) in micropolitan or non-core regions of the US. Participants’
average TAPS total score was 4.8 (SD = 1.6) points (range:
2–6 points). While all participants reported use of nonprescribed opioid pain relievers, 27 (67.5%) also reported
use of heroin and/or non-prescript8ion fentanyl. The
majority of participants (n = 36; 90.0%) had received
some form of treatment for their OUD during their lifetime, and over half had been prescribed MOUD (n = 24;
60.0%). Among the 36 participants who had received
treatment, ten (27.8%) reported receiving treatment from
an integrated treatment program. Of the ten participants
currently prescribed MOUD, two participants were currently receiving MOUD from an integrated treatment
program. Additional details about participants’ demographic and opioid use characteristics are available in
Table 1.

Preferences for integrated versus non‑integrated
treatment models
The qualitative section of the interviews was 45 to 60 min
in length. When asked about their preference for receiving integrated versus non-integrated care, nine participants preferred integrated models, sixteen preferred
non-integrated models, and six were more uncertain.
The six uncertain participants preferred the idea of integrating OUD and general medical care in theory but had
concerns that the reality of integrated care may be stigmatizing or not provide necessary support or services.
One participant explained, “I think [integrated care models] would save people who are suffering with an addiction a lot of stress, if there wasn’t such a stigma, if your
primary care doctor didn’t look at you like a scumbag for
having a substance abuse issue” (Identification Number:
101, Gender: Male, Age: 31 years). These tradeoffs were
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Table 1 Participant demographics, opioid use characteristics,
and treatment experiences
Participants
(n = 40)
Demographic characteristics
Age m (sd)

36.5 (10.9) years

Gender n(%)
Male

24 (60.0%)

Female

16 (40.0%)

Non-binary

0 (0.0%)

Race n(%)
White

36 (90.0%)

African American/Black

4 (10.0%)

Ethnicity n(%)
Hispanic or Latino

8 (20.0%)

Not Hispanic or Latino

32 (80.0%)

Regions of residence n(%)
Midwest

5 (12.5%)

Northeast

10 (25.0%)

Northwest

5 (12.5%)

Southeast

11 (27.5%)

Southwest

9 (22.5%)

Highest level of education n(%)
Less than high school

4 (10.0%)

High school degree/GED

12 (30.0%)

Some college

11 (27.5%)

Associate’s degree

4 (10.0%)

Bachelor’s degree

7 (17.5%)

Master’s degree

1 (2.5%)

Trade school

1 (2.5%)

Opioid use and treatment characteristics
Recency of opioid use n(%)
  Past week

10 (25.0%)

  Past month

6 (15.0%)

  Past 6 months

9 (22.5%)

  More than 6 months

15 (37.5%)

Treatment experiences n(%)
Current/past OUD treatment experience

36 (90.0%)

Current/past MOUD prescription

24 (60.0%)

reflected in participants’ discussion of perceived advantages and disadvantages of integrated treatment models
(Table 2).
Perceived advantages and disadvantages of integrated
treatment models: Patient values
Patient values: Advantages of integrated treatment models

The opportunity for treatment personalization was valued as an advantage of integrated treatment. Some participants described encountering a “one-size-fits-all”

–

Effectiveness at treating OUD

Provider training in treating substance use –

“A [general medical provider] can probably do the medical part, but I still
think a person still needs that treatment.”
-131, Female, 36 years

–

(2021) 16:8

Counseling

–

“To get the license to prescribe [buprenorphine], apparently, it’s a very, very
short course. There’s a lot to addiction. I mean, it’s a very complex thing.
And it’s just not a one plus one is two… I don’t think they [general medical
providers] have the amount of education for it.”
–112, Male, 34 years

“I think that [integrated treatment] would help a lot of people. It would
probably help a lot of people because it costs moey to get clean like that
[non-integrated treatment models]… Like, going to the Suboxone doc‑
tor’s like hundreds and hundreds of dollars a month.”
–113, Female, 38 years

Cost

Access to services

“I don’t know if I would necessarily talk to my primary care doctor [about my
OUD] because I don’t think it would be beneficial at all.”
–104, Female, 25 years

“I wouldn’t have to wait to get approval to get seen.”
–105, Female, 31 years

Speed of access

“I think you’d have to make a doctor’s appointment, and sometimes you have
to wait a long time before you can see a doctor. I think that would be a con
[of integrated models] because I know when I go to see my doctor, I have
to wait a frickin’ month before I can see him.”
–107, Male, 52 years

“I mean, he [primary care doctor] is right in the same town that I live in, and
it just would have been convenient.”
–116, Female, 29 years

–

–

Convenience
Ease of access

Characteristics of setting and provider

“The cool part about doing everything with him [general medical provider]
would be that it would be really personal.”
–105, Female, 31 years

Individualization

“My struggle with addiction isn’t something that I readily share with [general
medical providers]. One, because I want the doctor to not ever prescribe
me pills again. And two, especially now that our entire healthcare system
has moved to electronics, I don’t really have any state privacy.”
-138, Male, 33 years

–

Fear of consequences

Non-integrated models

“When you go to a treatment program and stuff, it’s public. They’re not sup‑ “I would like to go to a private facility that nobody knew about… and they
posed to say anything, but it kinda becomes a public record. I mean, word
don’t share information with anybody else. I just want to focus on getting
gets out quick.”
better, as opposed to what else is going on with this information.”-135,
-140, Male, 40 years
Male, 30 years

Integrated models

Privacy and confidentiality

Patient values

Theme

Factors influencing preferences for:

Table 2 Perceived advantages and disadvantages of integrated treatment models: Emergent themes and representative quotes organized using
the Bastemeijer et al. (2017) taxonomy
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“They’re [general medical providers] trusted, and I already know who they
are. It’s a good way, going with whatever the doctor that you have.”
–-132, Male, 28 years

“I feel comfortable talking with him [general medical provider] about every‑
thing. And the people at the clinic.”
-110, Female, 32 years
“They [general medical providers] just make you feel like you’re a person
and not just like a frickin’ junk box.”
–110, Female, 32 years

Trust

Comfort discussing substance use

Compassion

“Most people in the medical field, a lot of them don’t show that caring… It’s
just a cattle call.”
–102, Male, 57 years

“If I was put in a situation where I would have to go talk to my doctor about
my drug usage, I definitely would not feel comfortable with that.”
–127, Male, 33 years

“I don’t even trust [general medical providers] anymore. Like after everything
I’ve been through, I don’t even trust doctors. I feel like it’s all a scam. I feel
like they’re just out to make money… That’s it. They don’t really want to
help you.”
-113, Female, 38 years

“He [general medical provider] knows all about my history, and that’s some‑ “She treated me differently once she found out I was an addict. I felt like
thing that was really important to me in a doctor, to find somebody who I
everything shifted.”
could be honest with, because you know, what good is it if you can’t be.” –115, Female, 35 years
–116, Female, 29 years

Past experiences of disclosure

“I went to [a general medical provider], and he was asking me some ques‑
tions about do I use. And I really was like, ‘I don’t want to tell this man that!’
‘Cause people look at you differently when they have to take care of you
then. It seems like he did after I told him.”
–-131, Female, 36 years

“When it comes to life or death, wouldn’t you want somebody, like your
doctor, that you’ve met over and over again? That you felt a connection
with?”
–119, Male, 42 years

Pre-existing relationship

Patient-provider relationship

–

Structure and support

“The negative part about going to [a general medical provider] would be a
lack of knowledge or tools to help me, and not having other people there
who can support me. I would fully rely on him for treatment.”
–105, Female, 31 years

“I’d rather do [integrated treatment]. If you’re an addict and you’re trying to “I would probably go to a treatment program, and maybe if I had some other
stay clean, but you have to go somewhere every day where there’s a thou‑
people to talk to and I could talk to people about what I’m going through, I
sand other addicts there, that’s not good for people.”
wouldn’t feel as bad because I would hear their stories and stuff.”
–115, Female, 35 years
–120, Female, 25 years

Peer support

Non-integrated models

Integrated models

Factors influencing preferences for:

Theme

Table 2 (continued)
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(122, Male, 37 years) approach to treating OUD at specialty substance use treatment programs.
“You go into a place at the rehab, or you go to a
place that deals with substance abuse… Like the
second you walk in, they automatically label you as
every other addict in the world… They don’t individualize [treatment]. Especially, like with group counseling. They’re just like, ‘OK, there’s 20 people in this
room. So you all should deal with it like this.’ That’s
not how we work. It doesn’t work for everyone” (104,
Female, 25 years).
Several participants believed that integrated models of care may have less rigid treatment plans and valued the opportunity to individualize treatment based on
their own desires and needs. A participant described her
experience in an integrated treatment setting, explaining,
“[My primary care provider] was willing to work with me
on a more individual approach… She allowed me, when I
was in outpatient, she was like, ‘So instead of these four
AA meetings that you have to sign for, you can go to
two, and then there’s also this SMART Recovery’” (139,
Female, 24 years).
Patient values: disadvantages of integrated treatment
models

A desire for anonymity was expressed by participants
and was generally viewed as a disadvantage of integrated
treatment for OUD. Participants often felt that receiving
treatment integrated into general medical settings was
less private and confidential than non-integrated treatment. For some, these concerns centered on the number
of providers encountered in general medical settings.
“Anonymity is a big thing… When you go see a doctor,
a nurse goes through everything first, before the doctor
comes in. So now you got the nurse knowing what you
are in here for. When you’re a drug addict or an alcoholic,
it’s kind of a secret. I don’t think too many people would
go for [integrated treatment]” (107, Male, 52 years). These
concerns appeared heightened by dual relationships with
general medical providers for a few rural patients. “I
live in such a small town. Everybody knows everybody’s
business. Let me just put it this way: One of the medical
attendants is actually my neighbor. So, I know she knows
everything that’s within my chart” (135, Male, 30 years).
Participants also had concerns that their medical records
were accessible by too many individuals in general medical settings. “Now that our entire healthcare system has
moved to electronics, I don’t really have any state privacy.
So honestly in the past, I’ve never felt comfortable sharing these things with a primary care doctor” (138, Male,
33 years). Though participants generally expressed awareness that treatment received at specialty substance use
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treatment programs was protected by federal regulations,
there was uncertainty regarding the rules for protecting
OUD treatment information within general medical settings. “As far as therapists go, they have the whole confidentiality oath that they have to go ahead and respect.
And I don’t know if doctors are the same. I mean, I know
they have the Hippocratic Oath, but that’s another thing”
(127, Male, 33 years). Only one participant thought integrated models may be more private than non-integrated
models, explaining that “when you go to a [substance
use] treatment program, it’s public. They’re not supposed
to say anything, but it kinda becomes a public record. I
mean, word gets out quick” (140, Male, 40 years).
Participants also worried about the personal consequences of disclosing their OUD in general medical settings, specifically expressing concerns about being denied
medications (e.g., “they’ll push that red button on the
computer, and you’ll never get an opiate for the rest of
your life” [119, Male, 42 years]), losing insurance coverage (e.g., “a lot of insurance companies might use that
information adversely to me” [135, Male, 30 years]), or
being reported to the legal system (e.g., “that’s why a lot
of people don’t ask for help, because of the legal issues”
[106, Female, 29 years]). One participant summarized
these concerns, explaining “[Integrated models] would
scare people off, because [people] don’t want to go ahead
and get their medical plan messed up or they probably
don’t want to be reported… I wouldn’t want to be in talking to any authority that’s going to be able to affect my
life by being honest” (127, Male, 33 years). In multiple
cases, participants described experiences in which their
medical treatment was altered after disclosure of nonprescribed opioid use, including treatment for migraine,
mental health conditions, and chronic pain.
“A specialty setting is probably better, I would
think… I went in to [a general medical setting] to
get headache medicine refilled… And they treated
me like I was a criminal when I went in there. They
asked me to do a drug test, which I wasn’t opposed
to, I didn’t mind, but she also asked me if I abuse
my medicine, which it can’t be abused… I never got
my headache medicine that she still never called in.
Had to fight with them for a week, and then I never
went back” (114, Female, 27 years).
Perceived advantages and disadvantages of integrated
treatment models: characteristics of the provider
and setting
Characteristics of the provider and setting: advantages
of integrated treatment models

Unanimously, participants thought that integrated
care models were “a lot more convenient” (134, Female,
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53 years) than non-integrated models, as they were often
geographically closer, faster to access, and less expensive than specialty substance use treatment programs.
Some participants appreciated being able to receive
treatment for their substance use in the same setting as
they received other health care. Participants described
encountering lengthy waiting lists and delays in receiving insurance approval prior to engaging in OUD treatment in non-integrated settings. Participants, therefore,
felt that receiving OUD treatment in a general medical
setting would expedite this process. “[Integrated treatment] is good so that you have access, but you don’t have
to wait for help” (106, Female, 29 years). Similarly, several
participants thought integrated models might reduce the
costs of treatment for patients. “The primary care doctor
would have been such a great thing to do instead of having to go to a specialist that charges more money” (113,
Female, 38 years). No participants perceived non-integrated models to be more convenient, cheaper, or easier
to access.
Characteristics of the provider and setting: Disadvantages
of integrated treatment models

Though convenience was a distinct advantage for integrated models, participants reported significant doubts
regarding the effectiveness of integrated models on
treating OUD. More than half of participants expressed
uncertainties about general medical providers’ abilities to treat opioid use successfully. “I guess if I had to
choose… I think I would still want to go to a [non-integrated model] to get help because I feel like it’s probably
the most effective way to get treatment because they have
these programs that are specifically designed for you and
your addiction” (105, Female, 31 years).
A quarter of participants thought that general medical providers are not qualified to treat OUD because
“they’re not educated on it” (115, Female, 35 years). Participants believed most general medical providers had
little training on substance use or OUD. “I’ve heard that
most doctors don’t have much knowledge with addiction.
So, I don’t feel like they should be prescribing [MOUD]
unless they’ve gone to school for quite a while, and they
have a lot of knowledge about how to go about treating
addiction. It’s way more than just writing a prescription”
(137, Female, 45 years). Several participants felt that
asking a general medical provider to treat OUD, rather
than a psychiatrist, psychologist, or counselor, was “asking to fail” (111, Male, 30 years) and thought general
medical providers “don’t have any business prescribing
[MOUD] because that’s not their specialty” (109, Female,
32 years). Many participants therefore expressed a desire
to receive treatment from a provider who specialized in
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treating substance use and had more in-depth training
and knowledge about OUD.
“They [a primary care physician] deal with such a
wide variety of illnesses that, I don’t want to say that
they couldn’t handle it, but what I have is severe. So
that’s why I prefer a [specialist]. But, I mean that’s
what primary care was, they were Google before
Google” (111, Male, 30 years).
A lack of time in general medical settings was identified as potentially reducing the effectiveness of integrated
treatment models. “My primary care doctor has no time
to do the Suboxone. It’s not fair to him” (124, Male,
65 years).
Others doubted that the context of general medical
settings would be conducive to providing effective treatment, perceiving these settings to lack structure and
support. Though participants desired the opportunity
to individualize their treatment, they emphasized the
importance of easy access to psychosocial services, if
desired. Concerns, therefore, that integrated models may
fall short by not facilitating access to counseling or peer
support were common.
“I personally haven’t heard of [general medical providers] prescribing Suboxone in relation with groups
or continuing care at all. The ones that you go to,
they kind of put that on you, but if there was a silver
bullet to fix all this shit, it’s not Suboxone by itself
provided by a prescriber. That’s wonderful that they
can do that, but there needs to be other support. If
they’re not providing it, they should facilitate it being
available, if nothing else” (136, Male, 34 years).
While many participants desired peer support, one
participant thought that reduced contact with other people with OUD was an advantage because of the decreased
risk of interaction with people who were actively using.
Perceived advantages and disadvantages of integrated
treatment models: Patient‑provider relationship
Patient‑provider relationship: Advantages of integrated
treatment models

Participants who viewed having a pre-existing relationship with a general medical provider as an advantage
described having strong, positive relationships with
general medical providers. This was a facilitator of preference for integrated treatment, as several of these participants wanted to expand this positive relationship to
include treatment for their OUD. “It’s really hard to see
a medical professional in your most addicted state, and
they don’t know you at all. They don’t know your body,
and they don’t have any basis of comparison for before
you had this addiction. So yeah, it would have been
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great if my primary care was able to do it” (116, Female,
29 years). Many of these participants felt comfortable
discussing their substance use with general medical providers. “I do feel comfortable talking to my [primary care
provider]. Actually, she’s the best doctor I’ve ever had…
The first thing she does when she walks in, is she shakes
your hand. You don’t have a lot of doctors do that… I
thought that was unusual and from then on, I’ve trusted
her decision-making” (118, Male, 33 years).
Patient‑provider relationship: Disadvantages of integrated
treatment models

Conversely, other participants were not comfortable discussing their substance use with general medical providers and described negative relationships with providers.
These participants thought that general medical doctors
often did not approach substance use in a sensitive manner or expressed judgmental attitudes. “Any time that I’ve
gone to the doctor or even gone to the ER or the hospital
or anything like that, they’re literally like, ‘Do you have
any existing medical conditions? Do you have diabetes? Oh, do you smoke crack on the side?’ Like no, that
is not how we should approach that at all” (104, Female,
25 years). Though one participant viewed general medical providers as more compassionate than providers in
specialty settings, other participants expressed frustration with a lack of compassion and connection. “We don’t
treat human beings like human beings anymore. That’s
what drug addicts need. They need people that care”
(102, Male, 57 years). Providers working in specialty settings were perceived to be “just a lot nicer” (125, Male,
35 years) and have more knowledge and compassion
when discussing substance use.
Past experiences of disclosure in general medical
settings often impacted participants’ perceptions of
receiving treatment in integrated models. Participants
described experiencing stigma and judgement after confiding in general medical providers, explaining that these
providers then treated them like a “scumbag” (101, Male,
31 years) or a “criminal” (114, Female, 27 years; 127, Male,
33 years) after learning of their opioid use. “My [primary
care provider] treats me differently once she found out I
was an addict. I feel like everything shifted” (115, Female,
35 years). Seven participants described specific situations
in which general medical providers treated them differently after disclosure of substance use.
“One time I went into a pain management specialist,
and I told him that I was having withdrawals. I was
honest with him that I had been abusing opiates,
and I requested Suboxone. And he was a prescriber
of Suboxone… I had told him that I had been using
oxycodone. Because I had been. And my supply had
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run out, and I couldn’t find it, and I did use heroin a
few times, in that span, that run. My urine test came
back positive for opiates and not for oxycodone, so
because I was not truthful in his words, he just kind
of told me to beat it, which I thought was just cruel”
(101, Male, 31 years).
Fear of judgement, often stemming from these past
experiences of disclosure, was a major concern surrounding integrated care models. “There’s such a taboo, especially around a lot of behaviors, whether they’re sexual or
drug related. It is hard to find a [medical provider] that
isn’t kind of judgmental about that sort of thing” (116,
Female 29 years).
As a result of previous negative experiences and a belief
that “doctors have a lot of accountability in this epidemic”
(101, Male, 31 years), five participants lacked trust in
general medical providers. “For many years, primary care
doctors were prescribing a lot of opioids. So, I don’t know
if there’s a lot of people that trust them. A lot of those
doctors, they cashed in, and they’ve gone on. So, I don’t
know” (108, Male, 36 years). These participants did not
trust that general medical providers would sincerely look
out for their wellbeing, expressing that “I feel like doctors
are out to make money. That’s it. They don’t really want
to help you” (113, Female, 38 years). Aside from concerns about trusting providers, participants doubted that
general medical providers would trust a person with an
OUD. “There’s no level of trust inherent in a person who
is an addict. So, an addict going to a doctor and trying to
plead their case for whatever. I just feel like it carries a lot
less weight when you have a substance abuse issue” (101,
Male, 31 years). As a response to this mutual mistrust,
participants worried that their other medical concerns
may be overshadowed by their substance use and ignored
by their medical providers.

Discussion
Across the US, treatment for OUD has been increasingly
integrated into general medical settings to rapidly expand
capacity in the wake of the opioid overdose epidemic
[68]. In response to this epidemic and lack of capacity in
specialty treatment settings [4, 5], an increasing number
of individuals are accessing critical treatment for OUD in
non-specialty settings, including general medical settings
[12, 13]. These integrated programs are critical to reducing the rate of overdose deaths in the US by expanding
access to life-saving MOUD, which is still underutilized
in specialty settings [10, 11]. Emerging evidence also
suggests integrated MOUD and primary care models
can improve health-related quality of life and treatment
retention for patients with OUD [25, 28, 30–33]. Despite
the benefits of integrated treatment, little previous
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research has examined patient preferences for integrated
versus non-integrated OUD treatment models. Results of
this exploratory, qualitative study suggest that although
some participants would theoretically prefer receiving
OUD treatment integrated in general medical settings,
others prefer non-integrated treatment models. Participants considered the advantages and disadvantages of
integrated models in terms of their own values (desire for
anonymity, fear of consequences, a desire for personalizing treatment), characteristics of the provider and setting (convenience, perceived effectiveness, and access to
services), and their relationship with medical providers
(navigating a pre-existing relationship, past experiences
of disclosure, trust, comfort, stigma, and compassion).
These values, opinions about the provider and setting,
and patient-provider relationships were substantially
influenced by participants’ prior experiences with OUD
treatment and the general medical system.

Patient values and OUD treatment model
Participants valued a sense of anonymity when receiving OUD treatment and expressed concerns about the
privacy of care offered within integrated treatment models. These concerns were amplified by the ubiquitous use
of electronic health records in general medical settings.
Relatedly, participants dually considered the consequences of disclosing their OUD in terms of the impact
on their treatment and on other facets of their life, if this
information about their OUD were to be shared without
their permission. Research suggesting that substancerelated records are often accessible to providers within
integrated treatment settings, despite the 42 CRF Part 2
regulations, gives credence to participants’ privacy concerns [69]. At a policy level, clarifying rules and regulations protecting substance use treatment information
within integrated treatment models may be critical to
engaging patients. Integrated treatment programs should
also consider educating patients regarding how their
OUD treatment information will be protected within the
program’s health records and which staff will have access
to this information. This may be particularly important in
rural regions, where dual relationships between patients
and providers are more common [70–72].
The potential to personalize treatment was considered
an important advantage to integrated models of OUD
treatment. Participants perceived that general medical
settings may have less rigid OUD treatment pathways.
Patients seeking SUD treatment have widely expressed
a desire to be involved in planning their treatment [73–
75]. According to a recent review, forty-six studies have
explored individualized treatment approaches [76].
Individualized approaches typically involved 1) a needs
assessment and treatment planning to match patients
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to treatments, 2) delivery of treatment according to
patient preferences and needs, or 3) adapting treatment
to patients’ unique assets and challenges. Integrated programs could consider adopting clinical approaches identified in this review that supported the development of
individualized care, including encouraging patients to
share preferences, establishing caring relationships with
patients, and recommending a flexible continuum of care.

Provider characterisics and setting
In contrast, several characteristics of general medical providers and practices were considered disadvantages to receiving care through an integrated treatment
model. Though evidence demonstrates that MOUD with
minimal counseling can be highly efficacious [77–79],
participants still worried that many general medical settings would not offer psychosocial services or facilitate
access successfully. The components of OUD treatment
offered in general medical settings do vary widely across
practices [24, 80]. Treatment guidelines recommend that
OUD treatment integrated into primary care or general
medical settings should include counseling and other
psychosocial services in addition to MOUD [81, 82].
These recommendations suggest that integrated OUD
treatment in general medical settings contain four treatment components: 1) MOUD; 2) psychosocial services;
3) integrated care for physical and psychiatric problems;
and 4) education and outreach [24]. Despite these recommendations, many general medical practices struggle
to provide these services due to a lack of time, staff, and
financing [80]. Implementing specific integrated models,
like the Collaborative Care or the Embedded Behavioral Specialists models that co-locate a care manager or
behavioral health clinician onsite, could facilitate access
to psychosocial services [83, 84]. In regions where psychosocial services may be less accessible, general medical
settings providing OUD treatment should consider leveraging novel technologies to provide access to patients,
such as telepsychiatry [85, 86] or mobile health (mhealth)
applications [87–90].
Participants also expressed doubts about the ability of
general medical providers to effectively treat their OUD,
noting concerns about training. These concerns are often
mirrored by general medical providers, who have widely
reported feeling unprepared to treat substance use disorders [60, 91–95]. An opportunity to increase training and
education exists, as general medical providers in one survey study strongly believed treatment for OUD could be
effective and supported improving education and training [96]. General medical practices that plan to integrate
treatment for OUD should provide training beyond the
buprenorphine waiver training, including allocating time
for providers to participate in training and mentoring
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activities, such as the Provider Clinical Support System
for Medication-Assisted Treatment (PCSS-MAT; [97],
learning collaboratives [98], or Project Echo [99, 100].
In opposition to the perceived disadvantages of integrated treatment, participants unanimously agreed that
integrated treatment was more convenient and less costly
than non-integrated treatment. In studies exploring
preferences for integrated substance use and HIV care,
patients similarly valued having both health conditions
treated by a single set of providers in one setting [47,
48, 50]. Convenience and cost are well-established barriers to receiving specialty substance use treatment [6,
76, 101]. Some rural participants described lengthy commutes to obtain specialty substance use treatment, so the
geographic proximity of general medical settings was an
important advantage of integrated models. People with
OUD residing in rural settings are less likely to obtain
specialty substance use treatment [6], so integrated models may be critically important to providing access to care
in these regions.

Patient‑provider relationship
The patient-provider relationship was another factor
that strongly influenced preferences for integrated OUD
treatment models. Depending on each participant’s individual experiences and values, participants viewed this
relationship as either an advantage or disadvantage of
receiving treatment integrated in general medical settings. For participants with strong existing connections
with general medical providers, this established relationship was viewed as an advantage. Research suggests
that people generally feel more comfortable disclosing
substance use to those with whom they have a long and
trusting relationship [102], so it is therefore not surprising that this relationship may impact participants’ preferences for addressing their opioid use with a general
medical provider.
For other participants, previous experiences of stigma
and judgement from general medical providers contributed to an absence of trust, feelings of shame, and discomfort discussing their opioid use in general medical
settings. These experiences of stigma in medical settings
are barriers to utilizating health care in general [103–
105] and may likewise impact access to OUD treatment
in integrated settings. For patients who do seek treatment
despite past experiences of judgement or stigma, these
experiences can make patients more vigilant and magnify any negative interactions with medical providers in
the present [106]. The patient-provider relationship also
has potential effects on participants’ views of provider
competence and their concerns about privacy. Strong
and trusting patient-provider relationships can reduce
the impact of privacy concerns [107, 108], so the negative
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relationships described by some patients may intensify these privacy concerns. In addition, patients rate
emphatic providers as more competent [109, 110]. Therefore, considering interventions and methods to improve
the patient-provider relationship may support patient
engagement in integrated treatment.
Aside from viewing providers who specialize in addiction medicine as more knowledgeable and effective at
treating OUD, the majority of participants also thought
specialists would be less judgmental and more understanding. This opinion echoes findings of a recent qualitative study [105] in which people who injected drugs
thought addiction medicine specialists were more empathetic and helpful than general medical providers. A
review of studies examining attitudes toward patients
with OUD among health providers found that stigma
and negative attitudes are commonly held in medical settings [111]. Improving the patient-provider relationship
by mitigating stigma and judgement may be critical to
engaging people with OUD in integrated models of treatment. Effective interventions to reduce stigma in medical settings include communicating positive stories about
people with OUD and improving medical provider education about SUDs [112, 113]. The adoption of personfirst language (e.g., person with an opioid use disorder)
may also help reduce stigma in general medical settings
[114–117].

Limitations
This study recruited a relatively small, self-selected sample of people who were predominately White and not
Hispanic or Latino. The lack of racial and ethnic diversity among participants is a major limitation of this study.
Studies have clearly documented disparities in OUD
treatment access among people of color in the US [118–
120]. In addition, structural racism and experiences of
racial discrimination in healthcare settings may impact
individuals’ experiences with treatment [121–123] and
thereby influence their preferences for OUD treatment.
Moreover, recruitment materials and interviews were all
in English, hence excluding individuals without English
language proficiency, who may face additional barriers
and have different experiences with treatment than individuals who speak English. To better understand preference for treatment models, future research must include
more participants of color and participants without English language proficiency.
Using a TAPS cutoff of two or higher likely excluded
some individuals with less severe opioid use. Participants may represent a more severe sample than the general population of individuals with OUD in the US. The
attitudes and preferences of study participants could
be systematically different from people who were not
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interested in participating, as participants may have had
stronger opinions about this topic than those individuals who did not participate. Preferences and perceptions
are also influenced by past experiences. While some participants had experiences receiving OUD treatment, others had never received treatment. This study was unable
to systematically examine the impact of past treatment
experiences. Additionally, among those who had received
treatment, participants’ experiences with each treatment model may have varied substantially, which could
also impact preference. More participants were currently
receiving MOUD from non-integrated than integrated
programs. It is possible that individuals currently receiving treatment in a non-integrated setting may prefer
this setting, so future research should recruit from integrated programs in addition to non-integrated programs
in order to include more participants currently receiving
integrated treatment.”
Last, nine participants in this study were unable to
articulate a preference for integrated versus non-integrated treatment models. While some of these participants may indeed not have a strong preference, a lack
of understanding regarding the difference between integrated and non-integrated models is a concern. The
Treatment Model Comparison Chart was used to provide
definitions of integrated versus non-integrated care but
was not pre-tested prior to this study. A better understanding about how to most effectively articulate the differences in treatment models to patients is important to
strengthen future qualitative and quantitative studies of
preferences.

Conclusions
In this qualitative study, the majority of participants
preferred non-integrated OUD treatment offered in
specialty settings. Despite this, participants highlighted the convenience and the potential for treatment individualization in OUD treatment integrated
into general medical settings, but they expressed concerns about privacy, the effectiveness of treatment, and
a lack of access to psychosocial services. In addition,
participants emphasized the importance of the patientprovider relationship. Some participants worried that
general medical providers may be more judgmental,
describing past negative experiences after disclosing
their substance use in general medical settings. Others with strong and trusting relationships with general
medical providers felt this relationship was an advantage of integrated treatment models. Overall, the findings support expanding access to both integrated and
non-integrated treatment options for individuals with
OUD. Recommendations to make integrated OUD

Page 13 of 16

treatment more patient-centered include providing
or facilitating access to psychosocial services, educating patients on how their OUD treatment information
will be protected within the program’s health records,
incorporating approaches to allow the individualization
of care, allocating time for continuing provider education on treating OUD, and prioritizing empathy and the
patient-provider relationship.
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